ArticleComputational and structural biotechnology journal2025
INSIGHT: An integrated framework for safe and sustainable chemical and material assessment.
Article in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review on Predictive Models and Integration Strategies for Holistic Impact Assessment of Chemicals and Materials.Environmental science & technology · 2026Review
- BMDx2: A Tool for Integrating Toxicogenomics-Based Dose-Dependency Analysis and AOP-Based Mechanistic Insights.Small methods · 2025Article
- Recent Advances in Machine Learning Models for Predicting Toxicity of Inorganic Nanoparticles.Chem & bio engineering · 2025Review
- Going digital to boost safe and sustainable materials innovation markets. The digital safe-and-sustainability-by-design innovation approach of the PINK project.Computational and structural biotechnology journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
55 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The assessment of chemicals and materials has traditionally been fragmented, with health, environmental, social, and economic impacts evaluated independently. This disjointed approach limits the ability to capture trade-offs and synergies necessary for comprehensive decision-making under the Safe and Sustainable by Design (SSbD) framework. The EU INSIGHT project addresses this challenge by developing a novel computational framework for integrated impact assessment, based on the Impact Outcome Pathway (IOP) approach. Extending the Adverse Outcome Pathway (AOP) concept, IOPs establish mechanistic links between chemical and material properties and their environmental, health, and socio-economic consequences. The project integrates multi-source datasets (including omics, life cycle inventories, and exposure models) into a structured knowledge graph (KG), ensuring FAIR (Findable, Accessible, Interoperable, Reusable) data principles are met. INSIGHT is being developed and validated through four case studies targeting per- and polyfluoroalkyl substances (PFAS), graphene oxide (GO), bio-based synthetic amorphous silica (SAS), and antimicrobial coatings. These studies demonstrate how multi-model simulations, decision-support tools, and artificial intelligence-driven knowledge extraction can enhance the predictability and interpretability of chemical and material impacts. Additionally, INSIGHT incorporates interactive, web-based decision maps to provide stakeholders with accessible, regulatory-compliant risk and sustainability assessments. By bridging mechanistic toxicology, exposure modeling, life cycle assessment, and socio-economic analysis, INSIGHT advances a scalable, transparent, and data-driven approach to SSbD. This project aligns with the European Green Deal and global sustainability goals, promoting safer, more sustainable innovation in chemicals and materials through an integrated, mechanistic, and computationally advanced framework.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.